R Garrett Morgan1, Stephen J Ives, Ashley E Walker, Richard M Cawthon, Robert H I Andtbacka, Dirk Noyes, Lisa A Lesniewski, Russell S Richardson, Anthony J Donato. 1. aGeorge E. Wahlen Department of Veterans Affairs Medical Center bGeriatric Research Education and Clinical Center, Salt Lake City Geriatrics Research, Education, and Clinical Center (182), Veterans Administration Salt Lake City Health Care System cDivision of Geriatrics, Department of Internal Medicine, University of Utah School of Medicine dDepartment of Human Genetics, Eccles Institute of Human Genetics eDepartment of Surgery, University of Utah Health Sciences Center fDepartment of Exercise and Sports Science, College of Health, University of Utah, Salt Lake City, Utah, USA.
Abstract
OBJECTIVE: Telomere shortening in arteries could lead to telomere uncapping and cellular senescence, which in turn could promote the development of hypertension. METHODS AND RESULTS: To assess the novel role of arterial telomere dysfunction in hypertension, we compared mean telomere length (qPCR), telomere uncapping (serine 139 phosphorylated histone γ-H2A.X (γ-H2) localized to telomeres: ChIP), and tumor suppressor protein p53 (P53)/cyclin-dependent kinase inhibitor 1A (P21)-induced senescence (P53 bound to P21 gene promoter: ChIP) in arteries from 55 age-matched hypertensive and nonhypertensive individuals. Arterial mean telomere length was not different in hypertensive patients compared with nonhypertensive individuals (P = 0.29). Arterial telomere uncapping and P53/P21-induced senescence were two-fold greater in hypertensive patients compared with nonhypertensive individuals (P = 0.04 and P = 0.02, respectively). Arterial mean telomere length was not associated with telomere uncapping or P53/P21-induced senescence (r = -0.02, P = 0.44 and r = 0.01, P = 0.50, respectively), but telomere uncapping was a highly influential covariate for the hypertension group difference in P53/P21-induced senescence (r = 0.62, P < 0.001, η(p)(2) = 0.35). Finally, telomere uncapping was a significant predictor of hypertension status (P = 0.03), whereas mean telomere length was not (P = 0.68). CONCLUSION: Collectively, these findings demonstrate that arterial telomere uncapping and P53/P21-induced senescence are linked to hypertension independently of mean telomere length, and telomere uncapping influences hypertension status more than mean telomere length.
OBJECTIVE: Telomere shortening in arteries could lead to telomere uncapping and cellular senescence, which in turn could promote the development of hypertension. METHODS AND RESULTS: To assess the novel role of arterial telomere dysfunction in hypertension, we compared mean telomere length (qPCR), telomere uncapping (serine 139 phosphorylated histone γ-H2A.X (γ-H2) localized to telomeres: ChIP), and tumor suppressor protein p53 (P53)/cyclin-dependent kinase inhibitor 1A (P21)-induced senescence (P53 bound to P21 gene promoter: ChIP) in arteries from 55 age-matched hypertensive and nonhypertensive individuals. Arterial mean telomere length was not different in hypertensivepatients compared with nonhypertensive individuals (P = 0.29). Arterial telomere uncapping and P53/P21-induced senescence were two-fold greater in hypertensivepatients compared with nonhypertensive individuals (P = 0.04 and P = 0.02, respectively). Arterial mean telomere length was not associated with telomere uncapping or P53/P21-induced senescence (r = -0.02, P = 0.44 and r = 0.01, P = 0.50, respectively), but telomere uncapping was a highly influential covariate for the hypertension group difference in P53/P21-induced senescence (r = 0.62, P < 0.001, η(p)(2) = 0.35). Finally, telomere uncapping was a significant predictor of hypertension status (P = 0.03), whereas mean telomere length was not (P = 0.68). CONCLUSION: Collectively, these findings demonstrate that arterial telomere uncapping and P53/P21-induced senescence are linked to hypertension independently of mean telomere length, and telomere uncapping influences hypertension status more than mean telomere length.
Authors: Fabrizio d'Adda di Fagagna; Philip M Reaper; Lorena Clay-Farrace; Heike Fiegler; Philippa Carr; Thomas Von Zglinicki; Gabriele Saretzki; Nigel P Carter; Stephen P Jackson Journal: Nature Date: 2003-11-05 Impact factor: 49.962
Authors: Charles Matthews; Isabelle Gorenne; Stephen Scott; Nicola Figg; Peter Kirkpatrick; Andrew Ritchie; Martin Goddard; Martin Bennett Journal: Circ Res Date: 2006-06-22 Impact factor: 17.367
Authors: Bruce Alpert; Brian McCrindle; Stephen Daniels; Barbara Dennison; Laura Hayman; Marc Jacobson; Larry Mahoney; Albert Rocchini; Julia Steinberger; Elaine Urbina; Richard Williams Journal: Hypertension Date: 2006-06-12 Impact factor: 10.190
Authors: S J Ives; R H I Andtbacka; S-Y Park; A J Donato; J R Gifford; R D Noyes; L A Lesniewski; R S Richardson Journal: Acta Physiol (Oxf) Date: 2012-08-06 Impact factor: 6.311
Authors: R Garrett Morgan; Ashley E Walker; Daniel W Trott; Daniel R Machin; Grant D Henson; Kelly D Reihl; Richard M Cawthon; Eros L Denchi; Yu Liu; Samuel I Bloom; Tam T Phuong; Russell S Richardson; Lisa A Lesniewski; Anthony J Donato Journal: J Mol Cell Cardiol Date: 2018-11-29 Impact factor: 5.000
Authors: Anna E Dikalova; Arvind Pandey; Liang Xiao; Liaisan Arslanbaeva; Tatiana Sidorova; Marcos G Lopez; Frederic T Billings; Eric Verdin; Johan Auwerx; David G Harrison; Sergey I Dikalov Journal: Circ Res Date: 2019-12-19 Impact factor: 17.367
Authors: Bennett G Childs; Martina Gluscevic; Darren J Baker; Remi-Martin Laberge; Dan Marquess; Jamie Dananberg; Jan M van Deursen Journal: Nat Rev Drug Discov Date: 2017-07-21 Impact factor: 84.694